#United States #Exton #Clinical Services #Frontage Labs #Dr. Chandra Prakash

Frontage Laboratories Expands Leadership with Dr. Chandra Prakash

Frontage Laboratories, Inc. has exciting news as it welcomes Dr. Chandra Prakash, Ph.D., to its team as Senior Advisor in Clinical Services. This announcement was made on June 29, 2026, solidifying Frontage's commitment to strengthening its clinical research capabilities. Dr. Prakash, a prominent figure within the fields of drug metabolism and pharmacokinetics (DMPK), clinical pharmacology, and biotransformation, brings over 40 years of invaluable experience to the organization.

Dr. Prakash is internationally recognized for his significant contributions to understanding drug disposition and metabolic pathways, which greatly influence modern drug development. Throughout his illustrious career, he has been pivotal in advancing our knowledge of how drugs are processed in the body and their resultant effects, particularly in clinical settings.

In his new role at Frontage, Dr. Prakash will provide strategic guidance to enhance the organization’s Clinical Services division. His expertise will be vital in areas including clinical pharmacology study design, human ADME (Absorption, Distribution, Metabolism, and Excretion) assessments, and drug-drug interaction evaluations. Additionally, he will play a crucial role in advising on regulatory submissions, ensuring that Frontage maintains its high standards of compliance and excellence in clinical research.

Dr. Prakash's background is impressive; he has held esteemed positions at institutions such as Vanderbilt University and the University of Maryland and has served in senior scientific leadership roles at renowned companies including Agios Pharmaceuticals, Biogen, and Pfizer. His professional journey has led to numerous successful regulatory submissions, marking significant achievements in oncology, neurology, rare diseases, and metabolic disorders, showcasing his profound impact on the industry.

In addition to his practical experience, Dr. Prakash is a prolific author with nearly 300 peer-reviewed publications to his name, alongside contributions as an editor for prestigious journals like Current Drug Metabolism. His profound knowledge and insights will serve Frontage’s biopharmaceutical partners worldwide, guiding them through complex drug development processes.

Dr. Abdul Mutlib, Chief Strategy and Scientific Officer at Frontage, expressed great enthusiasm regarding Dr. Prakash joining the team. He praised Dr. Prakash as a "luminary in DMPK and clinical pharmacology," emphasizing his remarkable record in scientific leadership and regulatory achievements. This endorsement highlights the high expectations for Dr. Prakash’s role as Frontage continues to expand its clinical services and elevate its support for global biotech clients.

Frontage Laboratories is a US-based leading global Contract Research and Development Organization (CRO/CDMO) that provides an extensive range of fully integrated, science-driven services across the drug development spectrum. Since its inception in 2001, Frontage has grown into a pivotal player in the industry, with operations encompassing drug discovery, development, manufacturing, and clinical trials. With its headquarters in Pennsylvania and 28 facilities worldwide, Frontage supports diverse biopharmaceutical sectors in achieving their submission goals, making it a crucial asset to its partners.

In welcoming Dr. Prakash, Frontage reaffirms its commitment to delivering innovative and effective solutions in the realm of drug development—a mission paramount to bringing advanced therapies to patients in need. The company looks forward to leveraging Dr. Prakash's extensive expertise to further this goal, ensuring that they continue to provide best-in-class service within the biotechnology landscape.